05/27/2026
Massey Drugs supports the Alabama Board of Medical Examiners’ recent warning regarding “research-grade” peptides. Patient safety and quality matter, and products labeled as research-grade are not FDA-reviewed or held to the same manufacturing standards as prescription medications.
As a licensed 503A compounding pharmacy, Massey Drugs follows FDA guidance and uses pharmacy-grade ingredients sourced through compliant channels. We currently compound certain permitted peptide-related therapies, such as Sermorelin, and if additional peptides become approved for compounding under FDA regulations, we plan to evaluate offering select options that meet appropriate safety and quality standards.
To stay informed on peptide compounding updates, future availability, and regulatory developments, sign up to receive email updates through our peptide information page.
US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.
